CutisPharma announces initiation of manufacturing operations
The launch represents a a key milestone on the company's path to secure new product approvals from the FDA.
CutisPharma has announced the launch of manufacturing operations at its headquarters facility — a key milestone on the company's path to secure new product approvals from the FDA.
CutisPharma completed a major capital investment to bring the product manufacturing process in-house, including activities necessary to achieve full compliance with the FDA's current Good Manufacturing Practices, or cGMP, a set of rigorous quality and safety requirements considered the gold standard in the pharmaceutical industry. The production line will support CutisPharma's plan to file a New Drug Application (NDA) with the FDA for its lead pipeline drug, RM-01, as well as other drugs in the Company’s portfolio currently in development.
"Our entire team is excited to achieve the important goal of validation of our manufacturing equipment, processes and staff training," said Neal Muni, CEO of CutisPharma. "The initiation of manufacturing at our state-of-the-art Wilmington facility will allow CutisPharma to build our company’s infrastructure and significantly advance our portfolio of high-quality specialty pharmaceutical products."
CutisPharma celebrated its manufacturing milestone during a special event featuring Jay Ash, the state’s Housing and Economic Development Secretary.
“Pharmaceutical manufacturing benefits from Massachusetts’ strong innovation ecosystem and significant support for the advanced manufacturing sector,” said Ash. “The Baker-Polito administration is committed to investing in the Commonwealth’s manufacturing ecosystem by supporting workforce training efforts and manufacturing research and development. I look forward to working with CutisPharma to drive economic growth and job creation in Massachusetts.”
Along with its investment and validation process, CutisPharma has ramped up hiring of highly skilled research scientists, chemists, engineers and technicians. The company anticipates hiring more personnel to support a significant scale up in activities over the next few years as additional manufacturing is initiated in-house for future FDA-approved drugs.
"With this manufacturing milestone, we are well on our way to transforming CutisPharma into a full-scale, high-quality specialty pharmaceutical company," Muni said.
CutisPharma has aggressively invested in its research and development pipeline for new products and also enhanced its portfolio of FIRST® Unit-of-Use Prescription Compounding Kits. The kits are designed to improve accuracy and quality for pharmacists who need to compound certain medications for which there is no commercially available alternative.
Among the products made by CutisPharma is an omeprazole compounding kit that enables retail pharmacists to create a liquid solution for children and infants requiring an oral suspension formulation of this drug. The company also makes a vancomycin compounding kit that enables easy preparation of a liquid solution for patients unable to swallow capsules.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance